Found: 23
Select item for more details and to access through your institution.
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 12, p. 1944, doi. 10.1177/13524585221102584
- By:
- Publication type:
- Article
Body mass index as a predictor of MS activity and progression among participants in BENEFIT.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 8, p. 1277, doi. 10.1177/13524585211061861
- By:
- Publication type:
- Article
Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study.
- Published in:
- Multiple Sclerosis Journal, 2019, v. 25, n. 9, p. 1255, doi. 10.1177/1352458518789884
- By:
- Publication type:
- Article
Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials.
- Published in:
- Multiple Sclerosis Journal, 2019, v. 25, n. 4, p. 565, doi. 10.1177/1352458518763089
- By:
- Publication type:
- Article
MRI-based prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis using SVM and lesion geometry.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Evaluating the response to glatiramer acetate in relapsing–remitting multiple sclerosis (RRMS) patients.
- Published in:
- Multiple Sclerosis Journal, 2014, v. 20, n. 12, p. 1602, doi. 10.1177/1352458514527863
- By:
- Publication type:
- Article
Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal, 2012, v. 18, n. 10, p. 1466, doi. 10.1177/1352458512442438
- By:
- Publication type:
- Article
Sodium intake and multiple sclerosis activity and progression in BENEFIT.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Immunoglobulin M oligoclonal bands: Biomarker of targetable inflammation in primary progressive multiple sclerosis.
- Published in:
- Annals of Neurology, 2014, v. 76, n. 2, p. 231, doi. 10.1002/ana.24190
- By:
- Publication type:
- Article
Molecular mechanism underlying the impact of vitamin D on disease activity of MS.
- Published in:
- Annals of Clinical & Translational Neurology, 2014, v. 1, n. 8, p. 605, doi. 10.1002/acn3.91
- By:
- Publication type:
- Article
Long-term clinical outcomes in patients with CIS treated with interferon beta-1b: results from the 15-year follow up of the BENEFIT trial.
- Published in:
- Journal of Neurology, 2024, v. 271, n. 7, p. 4599, doi. 10.1007/s00415-024-12417-x
- By:
- Publication type:
- Article
Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE.
- Published in:
- Journal of Neurology, 2015, v. 262, n. 2, p. 326, doi. 10.1007/s00415-014-7558-6
- By:
- Publication type:
- Article
Proton magnetic resonance spectroscopy in primary and secondary progressive multiple sclerosis.
- Published in:
- NMR in Biomedicine, 2000, v. 13, n. 2, p. 57, doi. 10.1002/(SICI)1099-1492(200004)13:2<57::AID-NBM609>3.0.CO;2-5
- By:
- Publication type:
- Article
Clinical use of dimethyl fumarate in multiple sclerosis treatment: an update to include China, using a modified Delphi method.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2023, p. 1, doi. 10.1177/17562864231180734
- By:
- Publication type:
- Article
Clinical use of dimethyl fumarate in multiple sclerosis treatment: an update to include China, using a modified Delphi method.
- Published in:
- Therapeutic Advances in Neurological Disorders, 2023, v. 16, p. 1, doi. 10.1177/17562864231180734
- By:
- Publication type:
- Article
Foreword.
- Published in:
- European Neurology, 2014, v. 72, p. V, doi. 10.1159/000367611
- By:
- Publication type:
- Article
Association of Serum Neurofilament Light Chain Levels at Disease Onset With Disability Worsening in Patients With a First Demyelinating Multiple Sclerosis Event Not Treated With High-Efficacy Drugs.
- Published in:
- JAMA Neurology, 2023, v. 80, n. 4, p. 397, doi. 10.1001/jamaneurol.2023.0010
- By:
- Publication type:
- Article
Teriflunomide and Epstein-Barr virus in a Spanish multiple sclerosis cohort: in vivo antiviral activity and clinical response.
- Published in:
- Frontiers in Immunology, 2023, p. 01, doi. 10.3389/fimmu.2023.1248182
- By:
- Publication type:
- Article
Subgroups of the BENEFIT study: Risk of developing MS and treatment effect of interferon beta-1b.
- Published in:
- Journal of Neurology, 2008, v. 255, n. 4, p. 480, doi. 10.1007/s00415-007-0733-2
- By:
- Publication type:
- Article
Frequency of Multiple Sclerosis in Menorca, Balearic Islands, Spain.
- Published in:
- Neuroepidemiology, 2001, v. 20, n. 2, p. 129, doi. 10.1159/000054772
- By:
- Publication type:
- Article
Late-onset metachromatic leukodystrophy clinically presenting as isolated peripheral neuropathy: Compound heterozygosity for the IVS2+1G→a mutation and a newly identified missense mutation (Thr408Ile) in a Spanish family.
- Published in:
- Annals of Neurology, 2001, v. 50, n. 1, p. 108, doi. 10.1002/ana.1076
- By:
- Publication type:
- Article
Vitamin D as an Early Predictor of Multiple Sclerosis Activity and Progression.
- Published in:
- JAMA Neurology, 2014, v. 71, n. 3, p. 306, doi. 10.1001/jamaneurol.2013.5993
- By:
- Publication type:
- Article
Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required.
- Published in:
- Multiple Sclerosis (13524585), 2009, v. 15, n. 11, p. 1303, doi. 10.1177/1352458509107015
- By:
- Publication type:
- Article